Literature DB >> 28070497

Clozapine for mitochondrial psychosis.

Josef Finsterer1, Sinda Zarrouk-Mahjoub2.   

Abstract

Entities:  

Year:  2017        PMID: 28070497      PMCID: PMC5219592          DOI: 10.1016/j.ymgmr.2016.12.010

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
Letter to the Editor With interest we read the article by Demily et al. about a 30 year old male with neuropathy, ataxia, and retinitis pigmentosa (NARP) syndrome due to the mutation m.8993T > C, clinically manifesting as cerebellar ataxia, pyramidal syndrome, and psychosis [1]. Upon antipsychotic medication the patient developed dystonia, akathisia, and extrapyramidal symptoms with falls [1]. Switching to clozapine resolved psychosis but triggered fatigue, myoclonus, and falls. We have the following comments and concerns. Psychosis is an increasingly recognised phenotypic central nervous system (CNS) manifestation in various mitochondrial disorders (MIDs). Since MIDs are frequently multisystem disorders either already at onset or become multisystemic during the disease course, antipsychotic treatment becomes challenging due to its multiple CNS and extra-CNS side effects. Particularly difficult is the treatment of MID patients who additionally present with movement disorders, cardiac disease, or hematological involvement. Cardiac side effects of clozapine include dilated cardiomyopathy, myocarditis, long-QT syndrome, atrial fibrillation, and sudden cardiac death [2]. Did the patient develop any cardiac manifestations upon administration of antipsychotic drugs, in particular clozapine? MIDs may manifest also with hematological abnormalities, in particular anemia, thrombocytopenia, or eosinophilia [3]. Did the described patient develop hematological manifestations either as a manifestation of the genotype or as a side of clozapine, which may induce leucopenia and even agranulocytosis, anemia, and throbocytopenia [4]? How do the authors explain the extrapyramidal side effects of clozapine in the light of recent findings showing that clozapine metabolites exhibit a neuroprotective effect on dopaminergic neurons through inhibition of microglial NADPH oxidase [5]? It also should be discussed if the mutation occurred spontaneously or was inherited. Were first-degree relatives investigated for clinical manifestations of MIDs? Overall, this interesting case could profit from further studies on the interaction of clozapine with wild-type and mutated mitochondria and from cardiac, hematological and CNS monitoring during the further course.
  5 in total

Review 1.  A systematic review of clozapine induced cardiomyopathy.

Authors:  Mohammed Alawami; Cara Wasywich; Aleksandar Cicovic; Christopher Kenedi
Journal:  Int J Cardiol       Date:  2014-08-01       Impact factor: 4.164

2.  The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study.

Authors:  Jimmy Lee; Hiroyoshi Takeuchi; Gagan Fervaha; Valerie Powell; Amaal Bhaloo; Robert Bies; Gary Remington
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153

Review 3.  Hematological manifestations of primary mitochondrial disorders.

Authors:  Josef Finsterer
Journal:  Acta Haematol       Date:  2007-07-18       Impact factor: 2.195

4.  Low dose clozapine controls adult-onset psychosis associated with the neurogenic ataxia-retinitis pigmentosa (NARP) mutation.

Authors:  Caroline Demily; Charlyne Duwime; Alice Poisson; Nathalie Boddaert; Arnold Munnich
Journal:  Mol Genet Metab Rep       Date:  2016-12-13

5.  Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase.

Authors:  Lulu Jiang; Xuefei Wu; Shuo Wang; Shih-Heng Chen; Hui Zhou; Belinda Wilson; Chun-Yang Jin; Ru-Band Lu; Keqin Xie; Qingshan Wang; Jau-Shyong Hong
Journal:  J Neuroinflammation       Date:  2016-05-16       Impact factor: 8.322

  5 in total
  1 in total

1.  Authors' reply - Clozapine for mitochondrial psychosis.

Authors:  Caroline Demily; Charlyne Duwime; Alice Poisson; Nathalie Boddaert; Arnold Munnich
Journal:  Mol Genet Metab Rep       Date:  2017-02-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.